Vorinostat (SAHA), is among the first HDAC inhibitor to be approved by United States Food and Drug Administration (FDA) for the treatment of relapsed and refractory cutaneous T-cell lymphoma (50). Here, HDAC9 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.